JNCCN 360 - MM - Ongoing CE Activities

Editors:

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP

Advertisement

Advertisement

Ongoing CE Activities

Also Consider: Precision Hematology Webinar Series (0 Credits)

BCMA Who and When: Immunotherapies in Patients with RRMM

Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma

Case Challenges in Newly Diagnosed Multiple Myeloma

Clinical Update on B-Cell Maturation Antigen-Directed Therapies for Multiple Myeloma

Current Evidence and Guidelines for Treatment Selection for Relapsed/Refractory Multiple Myeloma

Guideline Recommendations for Treatment Selection and Sequencing in Relapsed/Refractory Multiple Myeloma

Harnessing the Potential of Novel Therapies in Multiple Myeloma

Multiple Myeloma: An Expert Discussion on the Role of Cytogenetics and Minimal Residual Disease

New and Emerging Therapies for Multiple Myeloma: Case Studies for Nurses

Oncology Today with Dr Neil Love: Current Role of Minimal Residual Disease Assessment in the Management of Multiple Myeloma and Chronic Lymphocytic Leukemia

Optimizing Triplet and Quadruplet Therapy Regimens in Multiple Myeloma

Overcoming Barriers to Care in Multiple Myeloma: Recognizing the Problem and Focusing on Solutions

Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic

Simulation Challenge in Diagnosing and Treating Hematologic Malignancies

Updates From the 2023 Summer Meetings: Bispecific Antibodies in Multiple Myeloma

Sections

NCCN Resources

Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved